| Patient | Nelson Mandela |
|---|---|
| Date of birth | 1943-07-18 |
| Identifiers | MRN HR-ML021-SYN; SSN (made up) 000-21-6718 |
| Document date | 2026-06-09 |
| Author | Thandiwe Mokoena, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Subsequent annual wellness visit; no new complaints. [S]
Mr. Mandela is an 82-year-old man with unfavorable intermediate-risk prostate cancer, seven weeks after his first leuprolide injection, who is due to start radiotherapy in about six weeks. He returns for his subsequent annual wellness visit and completed the health risk assessment beforehand. He finished four weeks of bicalutamide without trouble. Since the injection he has had mild hot flashes, three or four a week, which wake him about once a week; his energy is a little lower in the afternoons, but he still walks every morning. His mood is good and he notices no change in memory or concentration. He has had no breast tenderness, chest pain, breathlessness, or leg swelling. Urinary symptoms are unchanged and mild. He takes vitamin D daily. He has had no falls, emergency visits, or hospital stays in the past year. [S]
| Element | Detail |
|---|---|
| Visit | Subsequent annual wellness visit |
| Safety events | No falls, emergency visits, or hospital stays in the past year |
| Medicines | Leuprolide 22.5 mg every twelve weeks (second dose due in five weeks); cholecalciferol 1000 units daily; bicalutamide finished four weeks ago |
| Active conditions | Prostate cancer, unfavorable intermediate risk, on androgen deprivation before radiotherapy; low bone mass at the femoral neck |
| Functional status | Independent in all activities and instrumental activities of daily living |
Health risk assessment. Completed by the patient before the visit and reviewed during the visit. [S]
| Domain | Finding |
|---|---|
| Self-rated health | Good |
| Psychosocial | Busy with his foundation and visitors; close family and friends; no loneliness or low mood |
| Tobacco | Never used tobacco |
| Alcohol and drugs | No alcohol (AUDIT-C 0); no other drug use |
| Physical activity | Walks 30 to 45 minutes most mornings; light resistance exercises twice a week added for bone health |
| Nutrition | Regular balanced meals; dairy and leafy greens for calcium; weight up 0.6 kg since starting androgen deprivation |
| Sleep | Seven hours a night; hot flashes wake him about once a week |
| Activities of daily living | Independent |
| Instrumental activities of daily living | Independent; his assistant manages his calendar and he manages his own medicines |
| Home safety | Smoke detectors working; handrails on the stairs; good lighting |
| Falls | No falls this year; no fear of falling |
| Hearing and vision | Some difficulty hearing in crowded rooms; wears glasses; eye examination five months ago |
| Memory | No concerns |
| Pain | Occasional knee stiffness in the morning |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Slightly lower energy in the afternoons on androgen deprivation; weight up 0.6 kg; no fever or night sweats |
| Eyes | Negative | No change in vision |
| Ears, nose, mouth, and throat | Positive | Some difficulty hearing in noisy rooms |
| Cardiovascular | Negative | No chest pain, palpitations, or leg swelling |
| Respiratory | Negative | No cough, breathlessness, or sputum |
| Gastrointestinal | Negative | Bowels regular, about once a day, formed; no bleeding |
| Genitourinary | Positive | Mild urinary frequency, unchanged; no blood in the urine |
| Musculoskeletal | Positive | Mild morning knee stiffness; no bone pain |
| Integumentary | Negative | No new skin lesions |
| Neurological | Negative | No headache, weakness, or numbness |
| Psychiatric | Negative | Mood good; PHQ-2 score 0; no change in memory or concentration |
| Endocrine | Positive | Mild hot flashes three or four times a week on androgen deprivation; no breast tenderness |
12 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Bicalutamide 50 mg oral tablet, one tablet by mouth once daily for four weeks, to block the testosterone flare at the start of leuprolide | One tablet once daily for four weeks | Oral route | 2026-04-14 to 2026-05-12 | completed | S |
| Leuprolide acetate 22.5 mg injection (three-month depot), intramuscular, two doses twelve weeks apart (the second given at a primary care visit), about six months of androgen deprivation with radiotherapy | One injection every twelve weeks, two doses | Intramuscular route | 2026-04-21 to 2026-10-06 | completed | S |
| Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily | One tablet once daily | Oral route | 2026-04-14 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-06-09 | Body height | 183 | cm | S |
| 2026-06-09 | Body weight | 81 | kg | S |
| 2026-06-09 | Body mass index (BMI) [Ratio] | 24.2 | kg/m2 | S |
| 2026-06-09 | Systolic blood pressure | 132 | mm[Hg] | S |
| 2026-06-09 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-06-09 | Heart rate | 68 | /min | S |
| 2026-06-09 | Respiratory rate | 14 | /min | S |
| 2026-06-09 | Body temperature | 36.6 | Cel | S |
| 2026-06-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-06-09 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2026-06-09 | Total score [Mini-Cog] | 5 | {score} | S | ||
| 2026-06-09 | Total score [AUDIT-C] | 0 | {score} | S |
Vital signs recorded on 2026-06-09; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Constitutional | Well, alert, and upright; weight 81.0 kg, BMI 24.2 |
| Eyes | Pupils equal and reactive; near vision 20/30 with glasses |
| Ears | Canals clear; whispered-voice test missed on the left, passed on the right |
| Neck | No thyroid enlargement; no lymph nodes |
| Cardiovascular | Regular rhythm at 68 per minute; no murmur; no ankle swelling |
| Respiratory | Clear to auscultation bilaterally |
| Chest | No gynecomastia or breast tenderness |
| Abdomen | Soft and non-tender |
| Musculoskeletal | Mild crepitus in both knees without effusion; Timed Up and Go 10 seconds; rises from a chair without using his arms |
| Neurological | Alert and oriented; gait steady; Mini-Cog 5 of 5 |
| Psychiatric | Euthymic and engaged; judgment and insight intact |
| Skin | No suspicious lesions |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Adenocarcinoma of the prostate, NCCN unfavorable intermediate risk: cT1c, Grade Group 3 (Gleason 4+3), PSA 6.4 ng/mL, 3 of 14 cores, found after a rising PSA; synthetic modern detail linked to his publicly announced prostate cancer | active | confirmed | C61 | S — Synthetic grade, PSA, core count, stage, and risk group; the PSA rise, the biopsy-proven localized cancer that was not high grade, hormone therapy, and curative radiotherapy are from his doctors' and spokeswoman's public statements (D). |
| Hormone-sensitive prostate cancer | active | confirmed | Z19.1 | S — Synthetic status in the modern episode. |
| Short-term androgen deprivation therapy (six months, leuprolide), with monitoring of testosterone, bone density, metabolic and cardiovascular risk, hot flashes, mood, and cognition | active | confirmed | Z79.899 | S — Synthetic androgen deprivation plan; Z79.899 is used because ICD-10-CM has no specific code for GnRH agonist therapy. |
| History of pulmonary tuberculosis, treated, with no symptoms since | resolved | confirmed | Z86.11 | S — The 1988 tuberculosis is documented (D); the coding and the statement that it has not recurred are synthetic. |
Personalized prevention plan. A written copy was given to the patient. [S]
| Service | Status | Detail |
|---|---|---|
| Pneumococcal vaccine | Completed today | PCV20 given today; no earlier pneumococcal vaccine on record; no further doses needed |
| Recombinant zoster vaccine | Completed today | Dose 1 given today; dose 2 due in two to six months |
| Influenza vaccine | Due | High-dose vaccine when this season's supply arrives in the autumn |
| RSV vaccine | Due | A single dose is recommended at 75 and older; at the pharmacy before the winter |
| COVID-19 vaccine | Due | Recommended at his age with this season's vaccine in the autumn |
| Tetanus, diphtheria, and pertussis booster | Up to date | Tdap seven years ago; next dose due in three years |
| Colorectal cancer screening | Not indicated | Screening from 76 to 85 is selective; discussed, and not recommended for him now, given his age and his current cancer treatment |
| Bone density | Up to date | DXA eight weeks ago before androgen deprivation: femoral neck T-score -1.4, spine -0.6; repeat in one to two years |
| Cholesterol and statin decision | Completed today | Total cholesterol 184, HDL 52, LDL 112 mg/dL at the first visit; no diabetes or smoking. Risk calculators are not validated beyond 79, and evidence for starting a statin for primary prevention after 75 is limited; androgen deprivation adds some cardiometabolic risk. Not started after discussion; lipids and glucose again in one year on the androgen deprivation schedule |
| Lung cancer and abdominal aortic aneurysm screening | Not indicated | Never used tobacco |
| Hepatitis C and HIV screening | Not indicated | Outside the recommended age ranges and no risk factors |
| Depression screening | Completed today | PHQ-2 score 0 |
| Unhealthy alcohol use screening | Completed today | AUDIT-C score 0 |
| Cognitive assessment | Completed today | Mini-Cog 5 of 5 |
| Falls prevention | Completed today | Timed Up and Go 10 seconds; no falls; walking and resistance exercise continue |
| Hearing | Referred | Whispered-voice test missed on the left; audiology arranged |
| Eye examination | Up to date | Five months ago |
Immunizations given today: Pneumococcal conjugate vaccine PCV20; Recombinant zoster vaccine, dose 1 of 2 [S]
Guideline basis: CMID: Clinical Monitoring Intelligence Database, prostate cancer monograph (2026); Medicare Wellness Visits (Medicare Learning Network) (2026); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026); Adult Immunization Schedule by Age (2026)
Follow-up: Chronic-care follow-up in five weeks with the second leuprolide injection. Radiotherapy to start in about six weeks. Second zoster dose in two to six months. Audiology. Next annual wellness visit in one year. Next scheduled visit 2026-07-14: three-month follow-up on androgen deprivation before radiotherapy: PSA, testosterone, vitamin D, and side effects. [S]
Voluntary advance care planning discussion of about 20 minutes, with his consent. He named a health care agent, and a health care proxy form was completed; the agent is recorded in the chart and is not named here. He said that what matters most to him is being told the truth about his health, continuing his work for as long as he can, and making his own decisions. He chose not to record specific treatment preferences today. The plan will be revisited yearly and with any change in his health. [S]